Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study

被引：2
|
作者：
Panizo, Carlos [1 ]
Bekadja, Mohamed Amine [2 ]
Meddeb, Balkis [3 ]
Mendoza, Maria Rigoroso [4 ]
Truman, Matt [5 ]
Smith, Rodney [4 ]
Barate, Claudia [6 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] Univ Hosp Estab, Oran, Algeria
[3] Aziza Othmana Univ Hosp, Tunis, Tunisia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] F Hoffmann La Roche Ltd, Dee Why, Australia
[6] Univ Pisa, Pisa, Italy
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2971.2971
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2971
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A pilot study on the use of the ProMACE CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma
    Baldini, L
    Guffanti, A
    Gobbi, P
    Colombi, M
    Federico, M
    Avanzini, P
    Cavanna, L
    Pieresca, C
    Silingardi, V
    Maiolo, AT
    CANCER, 1997, 79 (06) : 1234 - 1240
  • [42] Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia
    Hill, Samuel Luke
    Davies, Andrew
    FUTURE ONCOLOGY, 2018, 14 (17) : 1691 - 1699
  • [43] Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma
    Mielke, F.
    Schneider-Obermeyer, J.
    Doerner, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) : 1056 - 1057
  • [44] Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy
    Zduniak, Alexandra
    Leveque, Emilie
    Perdrix, Anne
    Etancelin, Pascaline
    Menard, Anne-Lise
    Lenain, Pascal
    Contentin, Nathalie
    Pepin, Louis-Ferdinand
    Lepretre, Stephane
    Lemasle, Emilie
    Lanic, Helene
    Stamatoullas-Bastard, Aspasia
    Kammoun-Quique, Leila
    Tilly, Herve
    Bauer, Fabrice
    Jardin, Fabrice
    Camus, Vincent
    LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3340 - 3350
  • [45] First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study
    McQuillan, Andrew D.
    Macdonald, William B. G.
    Leahy, Michael F.
    Turner, J. Harvey
    BLOOD, 2011, 118 (21) : 1589 - 1589
  • [46] First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial
    Hainsworth, JD
    Litchy, S
    Lamb, MR
    Rodriguez, GI
    Scroggin, C
    Greco, FA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 36 - 42
  • [47] Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma
    Fabbri, Alberto
    Lenoci, Mariapia
    Gozzetti, Alessandro
    Chitarrelli, Ida
    Olcese, Francesca
    Raspadori, Donatella
    Gobbi, Marco
    Lauria, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (01) : 90 - 93
  • [48] Outpatient 131I-Rituximab Radioimmunotherapy for Non-Hodgkin Lymphoma A Study in Safety
    Calais, Phillipe J.
    Turner, John Harvey
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (08) : 732 - 737
  • [49] Combined treatment of a cutaneous non-Hodgkin lymphoma with Rituximab and polychemotherapy
    Reinerth, G.
    Bruch-Gerharz, D.
    Kruse, R.
    Bernhardt, A.
    Schulte, K.-W.
    HAUTARZT, 2007, 58 (04): : 295 - 296
  • [50] The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma
    Smolewski, Piotr
    Robak, Tadeusz
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (07) : 791 - 808
12345